Table 1.

Demographic, pathologic, and clinical outcomes of discovery and validation cohorts

CohortDiscovery—MSKCC (n = 188)Validation—TCGA (n = 421)
Median age (quartiles)61 (54,69)61 (52,70)
GenderMale—132 (70.2%)Male—275 (65.3%)
Female—56 (29.8%)Female—146 (34.7%)
RaceWhite—170 (90.4%)White—394 (93.6%)
Black—7 (3.7%)Black—14 (3.3%)
Other—11 (5.9%)Other—13 (3.1%)
Median tumor size—cm (quartiles)5.1 (3.4,8.5)5.5 (4.0,8.5)
Primary tumor (T stagea)
 pT173 (38.8%)204 (48.5%)
 pT213 (6.9%)50 (11.9%)
 pT398 (52.1%)162 (38.5%)
 pT44 (2.1%)5 (1.2%)
Regional lymph nodes (N stagea)
 pNx103 (54.8%)216 (51.3%)
 pN078 (41.5%)12 (2.9%)
 pN17 (3.7%)193 (45.8%)
Distant metastases (M stagea)
 pM0165 (87.7%)353 (83.8%)
 pM123 (12.3%)68 (16.2%)
AJCC Stage
 I71 (37.8%)199 (47.3%)
 II11 (5.9%)41 (9.7%)
 III82 (43.6%)111 (26.4%)
 IV24 (12.8%)70 (16.7%)
Fuhrman nuclear grade
 G12 (1.1%)7 (1.6%)
 G275 (39.9%)173 (41.1%)
 G388 (46.8%)174 (41.3%)
 G423 (12.2%)66 (15.7%)
UnknownNA1 (<1%)
Median follow-up for survivors (mo)3546
Overall 5-year survival84.3%61.1%
Median survival (95% CI)NA (82.3, NA)76.8 (69, NA)
Number of deaths21142
Number of deaths from RCC13102

NOTE: NA in median survival refers to not estimable.

  • aTNM Seventh edition.